Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front Med    2011, Vol. 5 Issue (3) : 271-276     DOI: 10.1007/s11684-011-0148-4
Towards the optimization of management of hepatocellular carcinoma
Xi Feng1, Madhava Pai1, Malkhaz Mizandari2, Tinatin Chikovani2, Duncan Spalding1, Long Jiao1, Nagy Habib1()
1. Division of Surgery, Department of Surgery and Cancer, Imperial College London, London W12 0NN, UK; 2. Tbilisi 1st Hospital University Clinic, High Technology Medical Center, Tbilisi 0144, Georgia
Download: PDF(276 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Hepatocellular carcinoma (HCC) is the fifth most common neoplasm in the world, closely correlated with viral hepatitis and liver cirrhosis. The vast majority of HCC patients present at a late stage and are unsuitable for surgery due to limited liver functional reserve. Tumors can involve major vessels or hilar structures, necessitating major liver resection and/or rendering liver resection unfeasible. A series of new technologies have been developed to optimise HCC management. Stem cell therapy improves impaired liver functional reserve prior to liver resection. Intravascular radiofrequency ablation recanalises the portal vein invaded by tumour thrombus and endobiliary radiofrequency ablation restores and extends biliary patency of the bile duct invaded by malignancy. Laparoscopic radiofrequency assisted liver resection minimizes blood loss and avoids liver warm ischemia, while increasing parenchymal sparing. These benefits combined maximize the safety of liver resection.

Keywords management      hepatocellular carcinoma (HCC)      radiofrequency (RF) ablation      laparoscopic liver resection      stem cell      intravascular RF ablation      endobiliary RF ablation     
Corresponding Authors: Habib Nagy,   
Issue Date: 05 September 2011
URL:     OR
Fig.1  Pre and post VesCoag ablation of the blood supply to a renal metastasis in segment III.
Fig.2  (A)After application of VesOpen, the blood flow of the right portal vein was restored ;( B) HCC+ tumor thrombus in right portal vein prior to application of VesOpen.
Fig.3  (A) Before application of EndoHPB, the biliary tree was totally obstructed;( B) After application of EndoHPB, the continuity of the biliary tree was restored.
Fig.4  Illustration of change of bilirubin of 9 patients who were Child’s B, 7 were converted to Child’s A after stem cell therapy.
Fig.5  The steps to achieve liver resection using laparoscopic Habib 4X.
Fig.6  Ideal steps toward optimisation of advanced HCC patient.
1 Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362(9399): 1907–1917
doi: 10.1016/S0140-6736(03)14964-1 pmid:14667750
2 Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94(2): 153–156
doi: 10.1002/ijc.1440 pmid:11668491
3 Simonetti RG, Cammà C, Fiorello F, Politi F, D’Amico G, Pagliaro L. Hepatocellular carcinoma: a worldwide problem and the major risk factors. Dig Dis Sci 1991; 36(7): 962–972 1649041
doi: 10.1007/BF01297149
4 Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130(7): 417–422
doi: 10.1007/s00432-004-0552-0 pmid:15042359
5 Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, Hung CH, Chen CH, Changchien CS, Hsu HC, Hu TH, Lee CM, Wang JH. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer 2010; 46(4): 744–751
doi: 10.1016/j.ejca.2009.12.018 pmid:20060710
6 Llovet JM, Bruix J, Gores GJ. Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology 2000; 31(4): 1019–1021
doi: 10.1053/he.2000.6959 pmid:10733561
7 Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33(6): 1394–1403
doi: 10.1053/jhep.2001.24563 pmid:11391528
8 Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002; 235(3): 373–382
doi: 10.1097/00000658-200203000-00009 pmid:11882759
9 Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954; 30(5): 969–977
10 Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxì A, Cottone M. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224(1): 47–54
doi: 10.1148/radiol.2241011262 pmid:12091661
11 Khorsandi S, Kysela P, Valek V, Olufemi O, Lázár I, Prochazka V, Zacharoulis D, Rountas C, Habib N. Initial data on a novel endovascular radiofrequency catheter when used for arterial occlusion in liver cancer. Eur Surg 2009; 41(3): 104–108
doi: 10.1007/s10353-009-0463-z
12 Khorsandi S, Zacharoulis D, Vavra P, Navarra G, Kysela P, Habib N. The modern use of radiofrequency energy in surgery, endoscopy and interventional radiology. Eur Surg 2008; 40(5): 204–210
doi: 10.1007/s10353-008-0427-8
13 Lau WY, Leung JWC, Li AKC. Management of hepatocellular carcinoma presenting as obstructive jaundice. Am J Surg 1990; 160(3): 280–282
doi: 10.1016/S0002-9610(06)80023-1 pmid:2168129
14 Loew BJ, Howell DA, Sanders MK, Desilets DJ, Kortan PP, May GR, Shah RJ, Chen YK, Parsons WG, Hawes RH, Cotton PB, Slivka AA, Ahmad J, Lehman GA, Sherman S, Neuhaus H, Schumacher BM. Comparative performance of uncoated, self-expanding metal biliary stents of different designs in 2 diameters: final results of an international multicenter, randomized, controlled trial. Gastrointest Endosc 2009; 70(3): 445–453
doi: 10.1016/j.gie.2008.11.018 pmid:19482279
15 Steel AW, Postgate AJ, Khorsandi S, Nicholls J, Jiao L, Vlavianos P, Habib N, Westaby D. Endoscopically applied radiofrequency ablation appears to be safe in the treatment of malignant biliary obstruction. Gastrointest Endosc 2011; 73(1): 149–153
doi: 10.1016/j.gie.2010.09.031 pmid:21184881
16 Alison MR, Poulsom R, Jeffery R, Dhillon AP, Quaglia A, Jacob J, Novelli M, Prentice G, Williamson J, Wright NA. Hepatocytes from non-hepatic adult stem cells. Nature 2000; 406(6793): 257
doi: 10.1038/35018642 pmid:10917519
17 Preston SL, Alison MR, Forbes SJ, Direkze NC, Poulsom R, Wright NA. The new stem cell biology: something for everyone. Mol Pathol 2003; 56(2): 86–96
doi: 10.1136/mp.56.2.86 pmid:12665626
18 Theise ND, Nimmakayalu M, Gardner R, Illei PB, Morgan G, Teperman L, Henegariu O, Krause DS. Liver from bone marrow in humans. Hepatology 2000; 32(1): 11–16
doi: 10.1053/jhep.2000.9124 pmid:10869283
19 Gordon MY, Levicar N, Pai M, Bachellier P, Dimarakis I, Al-Allaf F, M’Hamdi H, Thalji T, Welsh JP, Marley SB, Davies J, Dazzi F, Marelli-Berg F, Tait P, Playford R, Jiao L, Jensen S, Nicholls JP, Ayav A, Nohandani M, Farzaneh F, Gaken J, Dodge R, Alison M, Apperley JF, Lechler R, Habib NA. Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells 2006; 24(7): 1822–1830
doi: 10.1634/stemcells.2005-0629 pmid:16556705
20 Levicar N, Pai M, Habib NA, Tait P, Jiao LR, Marley SB, Davis J, Dazzi F, Smadja C, Jensen SL, Nicholls JP, Apperley JF, Gordon MY. Long-term clinical results of autologous infusion of mobilized adult bone marrow derived CD34+ cells in patients with chronic liver disease. Cell Prolif 2008; 41(Suppl 1): 115–125
doi: 10.1111/j.1365-2184.2008.00491.x pmid:18181952
21 Pai M, Zacharoulis D, Milicevic MN, Helmy S, Jiao LR, Levicar N, Tait P, Scott M, Marley SB, Jestice K, Glibetic M, Bansi D, Khan SA, Kyriakou D, Rountas C, Thillainayagam A, Nicholls JP, Jensen S, Apperley JF, Gordon MY, Habib NA. Autologous infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with alcoholic liver cirrhosis. Am J Gastroenterol 2008; 103(8): 1952–1958
doi: 10.1111/j.1572-0241.2008.01993.x pmid:18637092
22 am Esch JS 2nd, Knoefel WT, Klein M, Ghodsizad A, Fuerst G, Poll LW, Piechaczek C, Burchardt ER, Feifel N, Stoldt V, Stockschl?der M, Stoecklein N, Tustas RY, Eisenberger CF, Peiper M, H?ussinger D, Hosch SB. Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells 2005; 23(4): 463–470
doi: 10.1634/stemcells.2004-0283 pmid:15790766
23 Cuesta MA, Meijer S, Paul MA, de Brauw LM. Limited laparoscopic liver resection of benign tumors guided by laparoscopic ultrasonography: report of two cases. Surg Laparosc Endosc 1995; 5(5): 396–401
24 Pai M, Navarra G, Ayav A, Sommerville C, Khorsandi SK, Damrah O, Jiao LR, Habib NA. Laparoscopic Habib 4X: a bipolar radiofrequency device for bloodless laparoscopic liver resection. HPB (Oxford) 2008; 10(4): 261–264
doi: 10.1080/13651820802167862 pmid:18773100
25 Weber JC, Navarra G, Jiao LR, Nicholls JP, Jensen SL, Habib NA. New technique for liver resection using heat coagulative necrosis. Ann Surg 2002; 236(5): 560–563
doi: 10.1097/00000658-200211000-00004 pmid:12409660
26 Ayav A, Jiao L, Dickinson R, Nicholls J, Milicevic M, Pellicci R, Bachellier P, Habib N. Liver resection with a new multiprobe bipolar radiofrequency device. Arch Surg 2008; 143(4): 396–401 , discussion 401
doi: 10.1001/archsurg.143.4.396 pmid:18427028
27 Ayav A, Jiao LR, Habib NA. Bloodless liver resection using radiofrequency energy. Dig Surg 2007; 24(4): 314–317
doi: 10.1159/000103664 pmid:17657158
28 Jiao LR, Ayav A, Navarra G, Sommerville C, Pai M, Damrah O, Khorsandi S, Habib NA. Laparoscopic liver resection assisted by the laparoscopic Habib Sealer. Surgery 2008; 144(5): 770–774
doi: 10.1016/j.surg.2008.08.005 pmid:19081019
29 Akyildiz HY, Morris-Stiff G, Aucejo F, Fung J, Berber E. Techniques of radiofrequency-assisted precoagulation in laparoscopic liver resection. Surg Endosc 2011; 25(4): 1143–1147
doi: 10.1007/s00464-010-1330-5 pmid:20844897
[1] Nan Ding,Jiafei Xi,Yanming Li,Xiaoyan Xie,Jian Shi,Zhaojun Zhang,Yanhua Li,Fang Fang,Sihan Wang,Wen Yue,Xuetao Pei,Xiangdong Fang. Global transcriptome analysis for identification of interactions between coding and noncoding RNAs during human erythroid differentiation[J]. Front. Med., 2016, 10(3): 297-310.
[2] Yuting Tan,Han Liu,Saijuan Chen. Mutant DNA methylation regulators endow hematopoietic stem cells with the preleukemic stem cell property, a requisite of leukemia initiation and relapse[J]. Front. Med., 2015, 9(4): 412-420.
[3] Lanping Xu,Huanling Zhu,Jianda Hu,Depei Wu,Hao Jiang,Qian Jiang,Xiaojun Huang. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase[J]. Front. Med., 2015, 9(3): 304-311.
[4] Yingchen Li,Guoheng Hu,Qilai Cheng. Implantation of human umbilical cord mesenchymal stem cells for ischemic stroke: perspectives and challenges[J]. Front. Med., 2015, 9(1): 20-29.
[5] Hai Wang,Qian Zhang,Xiangdong Fang. Transcriptomics and proteomics in stem cell research[J]. Front. Med., 2014, 8(4): 433-444.
[6] Bao-Zhu Yuan,Junzhi Wang. The regulatory sciences for stem cell-based medicinal products[J]. Front. Med., 2014, 8(2): 190-200.
[7] Du Yan, Han Xue, Pu Rui, Xie Jiaxin, Zhang Yuwei, Cao Guangwen. Association of miRNA-122-binding site polymorphism at the interleukin-1 α gene and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk[J]. Front. Med., 2014, 8(2): 217-226.
[8] Yang Yang, Xiaofei Han, Jingyun Guan, Xiangzhi Li. Regulation and function of histone acetyltransferase MOF[J]. Front Med, 2014, 8(1): 79-83.
[9] Carmen Chak-Lui Wong, Alan Ka-Lun Kai, Irene Oi-Lin Ng. The impact of hypoxia in hepatocellular carcinoma metastasis[J]. Front Med, 2014, 8(1): 33-41.
[10] Douglas D. Fang, Joan Cao, Jitesh P. Jani, Konstantinos Tsaparikos, Alessandra Blasina, Jill Kornmann, Maruja E. Lira, Jianying Wang, Zuzana Jirout, Justin Bingham, Zhou Zhu, Yin Gu, Gerrit Los, Zdenek Hostomsky, Todd VanArsdale. Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line[J]. Front Med, 2013, 7(4): 462-476.
[11] Siming Yang, Kui Ma, Changjiang Feng, Yan Wu, Yao Wang, Sha Huang, Xiaobing Fu. Capacity of human umbilical cord-derived mesenchymal stem cells to differentiate into sweat gland-like cells: a preclinical study[J]. Front Med, 2013, 7(3): 345-353.
[12] Xiaodong Mo, Xiaojun Huang. Advancement of human leukocyte antigen-partially matched related hematopoietic stem cell transplantation[J]. Front Med, 2013, 7(3): 306-315.
[13] Beicheng Sun, Michael Karin. Inflammation and liver tumorigenesis[J]. Front Med, 2013, 7(2): 242-254.
[14] Jin Gao, Ben Panizza, Newell W. Johnson, Scott Coman, Alan R. Clough. Basic consideration of research strategies for head and neck cancer[J]. Front Med, 2012, 6(4): 339-353.
[15] Hongchi Jiang, Jizhou Wang. Emergency strategies and trends in the management of liver trauma[J]. Front Med, 2012, 6(3): 225-233.
Full text